Short answer
ENANTA PHARMACEUTICALS INC (ENTA) filed an 8-K current report with the SEC on June 23, 2026 reporting Item 8.01 (Other Events). Federal Circuit affirmed December 2024 summary judgment invalidating Enanta’s ’953 Patent.
ENANTA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Federal Circuit affirmed December 2024 summary judgment invalidating Enanta’s ’953 Patent
- Patent-infringement damages claim against Pfizer over Paxlovid manufacturing, use, and sales effectively defeated
- Decision removes potential litigation recovery tied to Paxlovid royalties or damages
- Enanta’s appeal concluded adversely, eliminating further relief through this case absent additional proceedings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ENANTA PHARMACEUTICALS INC 8-K filings
Get the next ENTA 8-K as it lands
Follow ENTA for push alerts, or ask the research agent what this filing means.